

Supplementary Material

Unveiling Palmitoyl Thymidine Derivatives as Antimicrobial/Antiviral Inhibitors: Synthesis, Molecular Docking, Dynamic Simulations, ADMET and Assessment of Protein-Ligand Interactions

##

Table of Contents

1. FTIR, ^1H and ^{13}C NMR spectral data of compounds (2-6).....	2
2. FTIR spectra of compounds (2-6)	5
3. ^1H and ^{13}C NMR spectra of compounds (2-6).....	6
4. Biological data	16
5. Tables	17

1. FTIR, ^1H and ^{13}C NMR Spectral data of compounds (2-6)

2.2.1. 5'-O-(Palmitoyl)thymidine (2)

FTIR: ν_{max} 1702 (-CO), 3406~3501 (br) (-OH), 3280 (-NH) cm^{-1} . ^1H -NMR (400 MHz, CDCl_3): δ_{H} 9.02 (1H, s, -NH), 7.28 (1H, d, $J = 1.8$ Hz, H-6), 5.80 (1H, t, $J = 6.4$ Hz, H-1'), 5.0 (1H, dd, $J = 12.2$ and 4.6 Hz, H-5'a), 4.92 (1H, dd, $J = 12.1$ and 3.7 Hz, H-5'b), 4.30 (1H, m, H-3'), 4.21 (1H, ddd, $J = 3.8$, 4.8 and 3.8 Hz, H-4'), 3.15 (1H, br s, 3'-OH), 3.88 (1H, ddd, $J = 13.6$, 6.5 and 4.5 Hz, H-2'a), 3.75 (1H, ddd, $J = 13.6$, 6.7 and 6.9 Hz, H-2'b), 2.32 {2H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 1.95 (3H, d, $J = 1.6$ Hz, 5- CH_3), 1.68 {2H, m, $\text{CH}_3(\text{CH}_2)_{12}\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.29 {26H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 0.90 {3H, m, $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }. ^{13}C -NMR (100 MHz, CDCl_3): δ_{C} 172.21 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 169.30 (C-1), 155.10 (C-4), 139.45 (C-3), 114.75 (C-2), 89.80 (C-1'), 87.20 (C-4'), 73.25 (C-3'), 64.25 (C-5'), 40.50 (C-2'), 16.10 (C-5), 34.43, 34.38, 31.95, 31.91 ($\times 2$), 29.52, 29.31, 29.11, 25.11 ($\times 2$), 24.77, 22.61, 21.54, 20.01 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 14.11 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }. LC-MS $[\text{M}+1]^+$ 481.60. Calcd. for $\text{C}_{25}\text{H}_{44}\text{O}_5\text{N}_2\text{CO}$: C=65.01, H=9.17; found: C=65.02, H=9.18%.

5'-O-Palmitoyl-3'-O-(pivaloyl)thymidine (3)

FTIR: ν_{max} 1720 (-CO), 3297 (-NH) cm^{-1} . ^1H -NMR (400 MHz, CDCl_3): δ_{H} 8.99 (1H, s, -NH), 7.28 (1H, d, $J = 1.8$ Hz, H-6), 5.93 (1H, t, $J = 6.6$ Hz, H-1'), 5.88 (1H, m, H-3'), 5.61 (1H, dd, $J = 12.0$ and 4.5 Hz, H-5'a), 5.47 (1H, dd, $J = 12.2$ and 3.6 Hz, H-5'b), 5.0 (1H, m, H-4'), 3.74 (1H, ddd, $J = 13.6$, 6.6 and 4.6 Hz, H-2'a), 2.37 {2H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 2.33 (1H, ddd, $J = 12.5$, 6.1 and 6.2 Hz, H-2'b), 1.95 (3H, d, $J = 1.3$ Hz, 5- CH_3), 1.65 {2H, m, $\text{CH}_3(\text{CH}_2)_{12}\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.32 {9H, s, $(\text{CH}_3)_3\text{CCO-}$ }, 1.29 {26H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 0.89 {3H, m, $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }. ^{13}C -NMR (100 MHz, CDCl_3): δ_{C} 176.90 {(CH_3) $_3\text{CCO-}$ }, 172.24 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 169.32 (C-1), 155.11 (C-4), 139.42 (C-3), 114.76 (C-2), 89.88 (C-1'), 87.23 (C-4'), 73.29 (C-3'), 64.26 (C-5'), 40.52 (C-2'), 16.13 (C-5), 38.88 {(CH_3) $_3\text{CCO-}$ }, 34.44, 34.35, 31.96, 31.92 ($\times 2$), 29.55, 29.34, 29.12, 25.15 ($\times 2$), 24.70, 22.62, 21.55, 20.02 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 27.11, 26.94, 26.86 {(CH_3) $_3\text{CCO-}$ }, 14.10 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }. LC-MS $[\text{M}+1]^+$ 564.78. Calcd. for $\text{C}_{30}\text{H}_{52}\text{O}_6\text{N}_2\text{CO}$: C=65.98, H=9.22; found: C=65.97, H=9.23%.

2.2.3. 3'-O-Lauroyl-5'-O-(palmitoyl)thymidine (4)

FTIR: $\nu_{\max}$ 1715 (-CO), 3298 (-NH) cm^{-1} . ^1H -NMR (400 MHz, CDCl_3): δ_{H} 9.0 (1H, s, -NH), 7.27 (1H, d, $J = 1.8$ Hz, H-6), 6.33 (1H, t, $J = 6.4$ Hz, H-1'), 5.59 (1H, m, H-3'), 5.36 (1H, dd, $J = 12.1$ and 4.5 Hz, H-5'a), 5.28 (1H, dd, $J = 12.0$ and 3.6 Hz, H-5'b), 5.09 (1H, ddd, $J = 3.8$, 4.8 and 3.8 Hz, H-4'), 2.69 (1H, ddd, $J = 13.4$, 6.4 and 4.4 Hz, H-2'a), 2.43 {2H, m, $\text{CH}_3(\text{CH}_2)_9\text{CH}_2\text{CO-}$ }, 2.36 {2H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 2.13 (1H, ddd, $J = 13.5$, 6.6 and 6.8 Hz, H-2'b), 1.94 (3H, d, $J = 1.6$ Hz, 5- CH_3), 1.68 {2H, m, $\text{CH}_3(\text{CH}_2)_8\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.62 {2H, m, $\text{CH}_3(\text{CH}_2)_{12}\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.29 {16H, m, $\text{CH}_3(\text{CH}_2)_8\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.27 {26H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 0.91 {3H, m, $\text{CH}_3(\text{CH}_2)_{10}\text{CO-}$ }, 0.90 {3H, m, $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }. ^{13}C -NMR (100 MHz, CDCl_3): δ_{C} 172.46 { $\text{CH}_3(\text{CH}_2)_{10}\text{CO-}$ }, 172.23 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 169.32 (C-1), 155.16 (C-4), 139.44 (C-3), 114.76 (C-2), 89.83 (C-1'), 87.22 (C-4'), 73.29 (C-3'), 64.23 (C-5'), 40.54 (C-2'), 16.12 (C-5), 34.43, 34.36, 31.97, 31.92 ($\times 2$), 29.53, 29.34, 29.17, 25.10 ($\times 2$), 24.79, 22.60, 21.52, 20.01 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 34.37, 31.90, 29.52 ($\times 2$), 29.10, 25.08 ($\times 2$), 22.05, 21.21, 20.11 { $\text{CH}_3(\text{CH}_2)_{10}\text{CO-}$ }, 14.10 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 13.49 { $\text{CH}_3(\text{CH}_2)_{10}\text{CO-}$ }. LC-MS $[\text{M}+1]^+$ 663.95. Calcd. For $\text{C}_{37}\text{H}_{66}\text{O}_6\text{N}_2\text{CO}$: C=68.78, H=9.95; found: C=68.79, H=9.97%.

2.2.4. 3'-O-Myristoyl-5'-O-(palmitoyl)thymidine (5)

FTIR: $\nu_{\max}$ 1725 (-CO), 3299 (-NH) cm^{-1} . ^1H -NMR (400 MHz, CDCl_3): δ_{H} 9.0 (1H, s, -NH), 7.26 (1H, d, $J = 1.3$ Hz, H-6), 6.22 (1H, t, $J = 6.5$ Hz, H-1'), 5.55 (1H, m, H-3'), 5.45 (1H, dd, $J = 12.0$ and 4.5 Hz, H-5'a), 5.20 (1H, dd, $J = 12.0$ and 3.5 Hz, H-5'b), 4.0 (1H, ddd, $J = 3.5$, 4.5 and 3.9 Hz, H-4'), 2.39 (1H, ddd, $J = 13.5$, 6.5 and 4.0 Hz, H-2'a), 2.36 {2H, m, $\text{CH}_3(\text{CH}_2)_{11}\text{CH}_2\text{CO-}$ }, 2.33 {2H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 2.27 (1H, ddd, $J = 13.5$, 6.5 and 6.7 Hz, H-2'b), 1.95 (3H, d, $J = 1.3$ Hz, 5- CH_3), 1.66 {2H, m, $\text{CH}_3(\text{CH}_2)_{10}\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.64 {2H, m, $\text{CH}_3(\text{CH}_2)_{12}\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.32 {20H, m, $\text{CH}_3(\text{CH}_2)_{10}\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.29 {26H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 0.92 {3H, t, $J = 6.6$ Hz, $\text{CH}_3(\text{CH}_2)_{12}\text{CO-}$ }, 0.91 {3H, m, $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }. ^{13}C -NMR (100 MHz, CDCl_3): δ_{C} 172.54 { $\text{CH}_3(\text{CH}_2)_{12}\text{CO-}$ }, 172.20 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 169.28 (C-1), 155.14 (C-4), 139.44 (C-3), 114.77 (C-2), 89.88 (C-1'), 87.23 (C-4'), 73.27 (C-3'), 64.26 (C-5'), 40.51 (C-2'), 16.16 (C-5), 34.44, 34.37, 31.96, 31.90 ($\times 2$), 29.51, 29.35, 29.10, 25.13 ($\times 2$), 24.76, 22.60, 21.55, 20.02 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 34.38, 34.12 ($\times 2$), 31.92, 29.59 ($\times 2$), 29.15, 24.96, 21.72 ($\times 2$), 20.09 ($\times 2$) { $\text{CH}_3(\text{CH}_2)_{12}\text{CO-}$ }, 14.12 { $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }, 14.01 { $\text{CH}_3(\text{CH}_2)_{12}\text{CO-}$ }. LC-MS $[\text{M}+1]^+$ 692.01. Calcd. for $\text{C}_{39}\text{H}_{70}\text{O}_6\text{N}_2\text{CO}$: C=69.64, H=10.13; found: C=69.63, H=10.14%.

2.2.5. 3'-O-(4-*t*-Butylbenzoyl)-5'-O-(palmitoyl)thymidine (**6**)

FTIR: $\nu_{\max}$ 1722 (-CO), 3298 (-NH) cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ_{H} 9.0 (1H, s, -NH), 8.03 (2H, m, Ar-H), 7.51 (2H, m, Ar-H), 7.29 (1H, d, $J = 1.8$ Hz, H-6), 6.38 (1H, t, $J = 6.4$ Hz, H-1'), 5.54 (1H, m, H-3'), 5.16 (1H, dd, $J = 12.1$ and 4.5 Hz, H-5'a), 3.86 (1H, dd, $J = 12.0$ and 3.6 Hz, H-5'b), 3.57 (1H, ddd, $J = 3.8, 4.8$ and 3.8 Hz, H-4'), 3.02 (1H, ddd, $J = 13.4, 6.4$ and 4.4 Hz, H-2'a), 2.47 {2H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 2.37 (1H, ddd, $J = 13.5, 6.6$ and 6.8 Hz, H-2'b), 1.95 (3H, d, $J = 1.6$ Hz, 5- CH_3), 1.66 {2H, m, $\text{CH}_3(\text{CH}_2)_{12}\text{CH}_2\text{CH}_2\text{CO-}$ }, 1.31, {9H, s, $(\text{CH}_3)_3\text{C-}$ }, 1.27 {26H, m, $\text{CH}_3(\text{CH}_2)_{13}\text{CH}_2\text{CO-}$ }, 0.91 {3H, m, $\text{CH}_3(\text{CH}_2)_{14}\text{CO-}$ }. $^{13}\text{C-NMR}$ (100 MHz, CDCl_3): δ_{C} 174.40 {(CH₃)₃CC₆H₄CO-}, 172.27 {CH₃(CH₂)₁₄CO-}, 169.35 (C-1), 155.17 (C-4), 139.43 (C-3), 132.44, 132.40, 130.94, 129.91, 126.52, 125.50 {(CH₃)₃CC₆H₄CO-}, 114.74 (C-2), 89.87 (C-1'), 87.25 (C-4'), 73.27 (C-3'), 64.20 (C-5'), 40.53 (C-2'), 16.14 (C-5), 34.45, 34.34, 31.97, 31.94 ($\times 2$), 29.53, 29.34, 29.15, 25.16 ($\times 2$), 24.72, 22.68, 21.55, 20.02 {CH₃(CH₂)₁₄CO-}, 35.67 {(CH₃)₃CC₆H₄CO-}, 14.13 {CH₃(CH₂)₁₄CO-}, 13.67, 13.65, 13.42 {(CH₃)₃CC₆H₄CO-}. LC-MS $[\text{M}+1]^+$ 641.86. Calcd. for $\text{C}_{36}\text{H}_{56}\text{O}_6\text{N}_2\text{CO}$: C=69.28, H=8.73; found: C=69.30, H=8.74%.

2. FTIR spectra of compounds (2-6)




Figure S1. FTIR spectra of the compound (2-6).

3. ^1H and ^{13}C NMR spectra of compounds (2-6)




Figure S2. ^1H -NMR spectra of the compound (2).





Figure S3. ^1H -NMR spectra of the compound (3).



Current Data Parameters
NAME
EXPNO
PROCNO

F2 - Acquisition Parameters
Date_ 20230313
Time_ 14.52
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg
TD 65536
SOLVENT CDC13
NS 16
DS 0
SWH 12019.230 Hz
FIDRES 0.183399 Hz
AQ 2.7262976 sec
RG 11.37
DW 41.600 usec
DE 6.50 usec
TE 298.4 K
D1 1.00000000 sec
TD0 1

===== CHANNEL f1 =====
SFO1 400.2340023 MHz
NUC1 1H
P1 11.20 usec
PLW1 12.00000000 W

F2 - Processing parameters
SI 131072
SF 400.2300000 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.00

Figure S4. ^1H -NMR spectra of the compound (4).




Figure S5. ¹H-NMR spectra of the compound (5).




Figure S6. ^1H -NMR spectra of the compound (6).




Figure S7. ¹³C-NMR spectra of the compound (2).




Figure S8. ^{13}C -NMR spectra of the compound (**3**).




Figure S9. ^{13}C -NMR spectra of the compound (4).





Figure S10. ¹³C-NMR spectra of the compound (**5**).



Current Data Parameters

NAME
EXPNO
PROCNO

F2 - Acquisition Parameters

Date_ 20230316
Time_ 16.50
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpg
TD 524288
SOLVENT CDCl3
DS 256
NS 0
SWH 25252.525 Hz
FIDRES 0.048165 Hz
AQ 10.3809023 sec
RG 208.5
DW 19.800 usec
DE 6.50 usec
TE 300.1 K
D1 1.00000000 sec
D11 0.03000000 sec
TDO 1

***** CHANNEL f1 *****

SFO1 100.6479778 MHz
NUC1 13C
P1 10.00 usec
PLW1 49.00000000 W

***** CHANNEL f2 *****

SFO2 400.2320011 MHz
NUC2 1H
CPDPRG2 waltz16
PCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.18584000 W
PLW13 0.15053000 W

F2 - Processing parameters

SI 1048576
SF 100.6379169 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.40

Figure S11. ^{13}C -NMR spectra of the compound (6).

3. Biological data




Figure S12. Experimental dishes of the synthesized test compounds **4**, **5** and **6** against (**left**); *B. cereus* and (**right**); *E. coli*, Here DMSO = Negative control and Azithromycin = Positive control.




Figure S13. Mycelial growth of the synthesized compound **3** against (**left**); *A. niger* and (**right**); *A. flavus*.

4. Tables

Table S1

Name of the pathogenic microorganisms.

Types of organisms	Strain	Reference
Gram-positive bacteria	<i>Bacillus subtilis</i>	ATCC 6633
	<i>Bacillus cereus</i>	BTCC 19
Gram-negative bacteria	<i>Escherichia coli</i>	ATCC 8739
	<i>Salmonella typhi</i>	AE 14612
	<i>Pseudomonas aeruginosa</i>	ATCC 9027
Name of the fungi	<i>Aspergillus niger</i>	ATCC 16404
	<i>Aspergillus flavus</i>	ATCC 204304

Table S2

The MIC values in mg/L of compounds **4** and **5** against tested organisms.

	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>S. typhi</i>	<i>P. aeruginosa</i>
4	0.45	6	8	1	8
5	2	6	1	0.5	8
Azithro	3	7	10	2	10

Table S3

The MBC values in mg/L of compounds **4** and **5** against tested organisms.

	<i>B. subtilis</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>S. typhi</i>	<i>P. aeruginosa</i>
4	8	16	16	8	16
5	8	16	12	8	8
Azithro	10	20	14	12	12